openPR Logo
Press release

Global Cancer Monoclonal Antibodies Pipeline Analysis

06-30-2017 09:43 AM CET | Health & Medicine

Press release from: PNS Pharma

In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies.

In recent years the popularity of monoclonal antibodies has increase many folds as they have revolutionized the treatments for cancer. The applications of Monoclonal antibodies, which are administered intravenously, include cancer cell marking, growth signal blocking, the delivery of chemotherapy toxins, and the reduction of new blood vessel growth. The understanding of these treatments is rapidly becoming an indispensable part of biotech investing, and investors need to clearly understand how monoclonal antibodies are affecting the industry.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Monoclonal-Antibodies-Pipeline-Analysis

“Global Cancer Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ongoing Monoclonal Antibodies being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cancer Monoclonal Antibodies market based upon development process.

Following parameters for each Monoclonal Antibodies drug profile in development phase are covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Orphan Designation

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Global Cancer Monoclonal Antibodies Drug Pipeline by Clinical Phase:

• Research: 68

• Preclinical: 240

• Phase-I: 112

• Phase-I/II: 29

• Phase-II: 73

• Phase-II/III: 5

• Phase-III: 31

• Preregistration: 3

• Marketed: 27

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Monoclonal Antibodies Pipeline Analysis here

News-ID: 603473 • Views: 200

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for Monoclonal

Global Custom Antibody Market | Types: Monoclonal, Polyclonal, Others
The Custom Antibody market report analyses the increasing demand for custom Antibody in different sectors like BioScience Companies, BioScience Research Institutions, Hospitals. The report consists with Key Players, Types, Applications & Regions. The Report consists of 109 pages with top 15 key players. Also, this report focuses on Custom Antibody market volume and value at the global level, regional level, and company level. From a global perspective, this report represents
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Cancer Monoclonal Antibodies Market: Top Manufacturers - AstraZeneca, Bay …
Latest industry research report on: Global Cancer Monoclonal Antibodies Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts This report studies Cancer Monoclonal Antibodies in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering F. Hoffmann-La Roche Amgen Bristol-Myers Squibb Takeda Pharmaceuticals AstraZeneca Bayer Merck Janssen Biotech Novartis OncoMed Pharmaceuticals Pfizer Eli Lilly Sanofi TG Therapeutics CTI BioPharma Intas
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.
Global Cancer Monoclonal Antibodies Market & Pipeline Insight
The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability